ESPE Abstracts (2014) 82 P-D-1-3-191

ESPE2014 Poster Presentations Pituitary (14 abstracts)

Phenotype Evaluation of Combined Pituitary Hormone Deficiency Caused By prop1 Gene Mutation in Comparison to Pituitary Deficiency Caused by Other Factors

Agata Zygmunt-Górska a, , Jerzy Starzyk a, , Małgorzata Wójcik a, , Ewa Madetko-Talowska b, , Piotr Sucharski b, , Izabela Herman-Sucharska c & Jacek J Pietrzyk b,


aDepartment of Pediatric Endocrinology, Chair of Pediatr, Kraków, Poland; bDepartment of Medical Genetics, Kraków, Poland; cDepartment of Radiology, Medical College, Jagiellonian University, Kraków, Poland; dPolish American Pediatrc Institute, Medical College, Jagiellonian University, Kraków, Poland


Background: Combine pituitary hormone deficiency (CPHD) may be caused by many factors. One – them is PROP1 gene mutation, that causes maldevelopment of GH, TSH, LH, FSH prolactin but not ACTH, producing cells (CPHD–PROP1).

Objective and hypotheses: The details of possible differences between phenotypes of CPHD–PROP1 and CPHD of other reasons (CPHD–nonPROP1) are not clear to date. The aim of the study was to determine the frequency of PROP1 gene mutation in CPHD patients and to compare the phenotypes of patients with CPHD–PROP1 and CPHD–non PROP1.

Method: In 74 (32 ♀) CPHD patients retrospective analysis of growth pattern, puberty, hormonal function, MRI of pituitary, PROP1 gene investigation were performed.

Results: PROP1 gene mutations were stated in 43 patients (58%), in remaining patients CPHD was caused by other inborn defects. CPHD–PROP1 in comparison to CPHD–non PROP1 patients presented with: higher birth weight (0.2 vs −0.3 SDS, P=0.02), perinatal abnormalities (n=1 vs 17), younger age at diagnosis (4.9 vs 8 years, P=0.006), less frequent neonatal hypoglycaemia (n=0 vs 4). At the moment of diagnosis there was no significant differences in height SDS (−4.1 vs −4.3), BMI SDS (0.22 vs 0.01). All patients presented with secondary hypothyroidism. The CPHD–PROP1 in comparison to CPHD–non PROP1 patients presented higher median GH peak value in stimulation tests (1.26 vs 0.87 ng/ml, P=0.02), less frequent secondary adrenal insufficiency (SAI) (2.4 vs 74%), however in 55% of CPHD–PROP1 patients SAI was recognized at later age. 92% of CPHD–non PROP1 and all CPHD–PROP1 patients who reached the age of puberty presented with hypogonadotrophic hypogonadism. In all CPHD–PROP1 patients MRI examination revealed smaller, normal or enlarged pituitary, ectopy of the posterior lobe in one CPHD–PROP1 patient and in eight CPHD–non PROP1.

Conclusions: PROP 1 gene mutation is the most common cause of CPHD in Polish population. Analysis of the birth, growth data, as well as hormonal status at the moment of diagnosis may indicate on PROP1 gene mutation. PROP1 gene investigation in CPHD patients might be helpful in order to anticipate SAI at later age.

Volume 82

53rd Annual ESPE (ESPE 2014)

Dublin, Ireland
18 Sep 2014 - 20 Sep 2014

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.